Home Cart Sign in  
Chemical Structure| 484-20-8 Chemical Structure| 484-20-8

Structure of Bergapten
CAS No.: 484-20-8

Chemical Structure| 484-20-8

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

5-Methoxypsoralen, a naturally occurring linear furocoumarin, has been successfully used in combination with ultraviolet (UV) A irradiation [psoralen plus UV (PUVA)] to manage psoriasis and vitiligo and inhibits proliferation in the human hepatocellular carcinoma cell line.

Synonyms: 5-Methoxypsoralen; 5-MOP; NSC 95437

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Bergapten

CAS No. :484-20-8
Formula : C12H8O4
M.W : 216.19
SMILES Code : O=C1C=CC2=C(O1)C=C(OC=C3)C3=C2OC
Synonyms :
5-Methoxypsoralen; 5-MOP; NSC 95437
MDL No. :MFCD00010272
InChI Key :BGEBZHIAGXMEMV-UHFFFAOYSA-N
Pubchem ID :2355

Safety of Bergapten

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335-H351-H361
Precautionary Statements:P261-P305+P351+P338

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
HFOB 200-400 µM 48 hours To evaluate cytotoxicity PMC10647757
HSF 200-400 µM 48 hours To evaluate cytotoxicity PMC10647757
U266 1190 µM (IC50) 96 hours Inhibited cell proliferation PMC10647757
HUVEC cells 2.5-40 μM 12 or 24 hours To evaluate the biocompatibility of Ber-lipo, results showed that Ber-lipo had good biocompatibility and Lipo significantly reduced the cytotoxicity of bergapten. PMC11474395
RAW264.7 cells 2.5-40 μM 12 or 24 hours To evaluate the biocompatibility of Ber-lipo, results showed that Ber-lipo had good biocompatibility and Lipo significantly reduced the cytotoxicity of bergapten. PMC11474395
Bone marrow-derived macrophages (BMDMs) 20 μM 2 hours Inhibited NLRP3 inflammasome activation, evidenced by attenuated cleaved caspase-1 and mature IL-1β release, as well as reduced ASC speck formation and subsequent gasdermin D (GSDMD)-mediated pyroptosis. PMC10462717
J774A.1 cells 20 μM 2 hours Inhibited NLRP3 inflammasome activation, evidenced by attenuated cleaved caspase-1 and mature IL-1β release, as well as reduced ASC speck formation and subsequent gasdermin D (GSDMD)-mediated pyroptosis. PMC10462717
RAW264.7 macrophages 62.5, 125, 250 μM 24 hours To evaluate the effect of Bergapten on NO and PGE2 production in RAW264.7 cells. Results showed that Bergapten significantly inhibited LPS-induced NO and PGE2 production. PMC9146895
Recombinant human CYP3A4 (rCYP3A4) 1.424 μM (IC50) 30 minutes Bergapten significantly inhibited the metabolism of tofacitinib in recombinant human CYP3A4, showing competitive inhibition PMC11033359
Human liver microsomes (HLMs) 2.647 μM (IC50) 30 minutes Bergapten significantly inhibited the metabolism of tofacitinib in human liver microsomes, showing competitive inhibition PMC11033359
Rat liver microsomes (RLMs) 2.619 μM (IC50) 30 minutes Bergapten significantly inhibited the metabolism of tofacitinib in rat liver microsomes, showing competitive inhibition PMC11033359
B16F10 melanoma cells 6.25, 12.5, 25 μM 48 hours To evaluate the effect of Bergapten on the expression of melanogenesis-related proteins, results showed that Bergapten significantly increased the protein expression levels of MITF, tyrosinase, TRP-1, and TRP-2. PMC9102055
B16F10 melanoma cells 6.25, 12.5, 25 μM 48 hours To evaluate the effect of Bergapten on the expression of melanogenesis-related proteins, results showed that Bergapten increased the expression of MITF, tyrosinase, TRP-1, and TRP-2. PMC9102055
ZR-75 20 μM and 50 μM 6 to 16 hours Bergapten induces autophagy by up-regulating PTEN expression, increasing Beclin1, PI3KIII, UVRAG, AMBRA expression and conversion of LC3-I to LC3-II PMC4498523
MCF-7 20 μM and 50 μM 6 to 16 hours Bergapten induces autophagy by up-regulating PTEN expression, increasing Beclin1, PI3KIII, UVRAG, AMBRA expression and conversion of LC3-I to LC3-II PMC4498523
B16F10 melanoma cells 6.25, 12.5, 25 μM 72 hours To evaluate the effect of Bergapten on melanogenesis, results showed that Bergapten significantly increased melanin content and tyrosinase activity. PMC9102055
B16F10 melanoma cells 1, 10, or 100 μM To evaluate the effect of Bergapten on melanin content and tyrosinase activity, results showed that Bergapten dose-dependently increased melanin content and tyrosinase activity in B16F10 cells PMC6812039
Rabbit jejunum 0.0026 mg/ml Bergapten exhibited concentration-dependent relaxation of both spontaneous and K+-induced contractions, similar to the effect of papaverine PMC9709249
RPMI8226 1272 µM (IC50) 96 hours Inhibited cell proliferation PMC10647757
SW620 354.5 µM (IC50) 96 hours Inhibited cell proliferation PMC10647757
HT-29 332.4 µM (IC50) 96 hours Inhibited cell proliferation PMC10647757
HOS 257.5 µM (IC50) 96 hours Inhibited cell proliferation PMC10647757
Saos-2 40.05 µM (IC50) 96 hours Inhibited cell proliferation, induced apoptosis PMC10647757

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
Mice High-fat diet and streptozotocin-induced diabetic mice Dietary supplementation 0.02% (w/w) For 10 weeks To evaluate whether bergapten and methoxsalen could prevent diabetes-induced osteoporosis and its underlying mechanism. Results showed that both bergapten and methoxsalen significantly reversed the decrease in serum osteocalcin, bone-alkaline phosphatase, and femur BMD, increased bone volume density and trabecular number, while decreasing the structure model index of femur tissue in diabetic mice. Additionally, these derivatives significantly reduced the number and formation of osteoclasts in diabetic bone tissue and downregulated the expression of osteoclast-related genes. PMC6471636
C57BL/6 mice Vitiligo model Transdermal administration 1% (w/w) Once daily for 12 days To evaluate the effect of Bergapten on hair pigmentation in vitiligo model mice, results showed that Bergapten significantly improved hair pigmentation PMC6812039
C57/B6 mice High-fat diet-induced diabetes-related osteoporosis model Oral 10 mg/kg/day and 20 mg/kg/day Once daily for 20 weeks Bergapten significantly inhibited RANKL-RANK signaling transduction, and suppressed the activation of the PI3K/AKT, JNK/MAPK and NF-κB signaling pathways, thus protecting trabecular structure and decreasing osteoclastogenic differentiation PMC5117769
Sprague Dawley rats Drug interaction model Oral 20 mg/kg and 50 mg/kg Single dose Bergapten significantly increased the plasma exposure (AUC) and maximum concentration (Cmax) of tofacitinib and decreased clearance (CLz/F), indicating inhibition of tofacitinib metabolism in vivo PMC11033359
C57BL/6J mice Escherichia coli-induced sepsis model Intraperitoneal injection 50 mg/kg 24 hours and 1 hour before injection Significantly ameliorated tissue inflammation and injury. PMC10462717
Mice Castor oil-induced diarrhea model Oral 50, 100, 200 mg/kg Single dose, observed for 4 hours Bergapten at doses of 50-200 mg/kg effectively reduced diarrheal secretions and intestinal secretions, showing antidiarrheal and antisecretory effects PMC9709249
Heracleum sosnowskyi Plant leaves Natural exposure to high temperature 2 days and 7 days To study the effect of high temperature on the content of Bergapten in Heracleum sosnowskyi, the results showed that the content of Bergapten significantly increased after 2 days and 7 days of high temperature treatment. PMC8124411

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT00533195 Atopic Dermatitis Phase 3 Completed - Austria ... More >> Medical University of Vienna; University Clinic of Dermatology; Division of Special and Environmental Dermatology Vienna, Austria, 1090 Less <<
NCT00811005 Pustular Palmoplantar Psoriasi... More >>s Less << Phase 3 Unknown October 2010 Austria ... More >> Medical University of Vienna; University Clinic of Dermatology; Division of Special and Environmental Dermatology Vienna, Austria, 1180 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

4.63mL

0.93mL

0.46mL

23.13mL

4.63mL

2.31mL

46.26mL

9.25mL

4.63mL

References

 

Historical Records

Categories